Zelluna Immunotherapy, an Oslo, Norway-based company focused on allogeneic “off the shelf” T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer, received an investment from Takeda Ventures, the strategic investing arm of Takeda.
The amount of the deal was not disclosed.
The company intends to use the funds to enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and continue the advancement of its platform with additional programs reaching the preclinical stage.
Led by Namir Hassan, CEO, Zelluna Immunotherapy is pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable.
TCR-NK products are a novel and proprietary class of allogeneic cell therapies that combine the inherent, pan-cancer killing mechanism, efficiency, and the allogeneic nature of NK cells with the targeting capabilities of TCRs. Arming NK cells with TCRs may unlock the potential to treat a wide range of currently untreatable cancers.
FinSMEs
25/08/2022